Qaiser Bashir

5.9k total citations
182 papers, 2.0k citations indexed

About

Qaiser Bashir is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Qaiser Bashir has authored 182 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Hematology, 66 papers in Molecular Biology and 60 papers in Oncology. Recurrent topics in Qaiser Bashir's work include Multiple Myeloma Research and Treatments (94 papers), Hematopoietic Stem Cell Transplantation (48 papers) and Acute Myeloid Leukemia Research (45 papers). Qaiser Bashir is often cited by papers focused on Multiple Myeloma Research and Treatments (94 papers), Hematopoietic Stem Cell Transplantation (48 papers) and Acute Myeloid Leukemia Research (45 papers). Qaiser Bashir collaborates with scholars based in United States, Israel and United Kingdom. Qaiser Bashir's co-authors include Richard E. Champlin, Muzaffar H. Qazilbash, Uday Popat, Michael C. Perry, Gabriela Rondón, Justin D. Floyd, Duc T. Nguyen, Donald C. Doll, Stefan O. Ciurea and Partow Kebriaei and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Qaiser Bashir

178 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Qaiser Bashir United States	22	1.4k	762	745	273	273	182	2.0k
Sandrine Meyer‐Monard Switzerland	21	1.0k 0.7×	607 0.8×	522 0.7×	198 0.7×	232 0.8×	42	1.8k
Jacques‐Olivier Bay France	25	891 0.6×	702 0.9×	721 1.0×	386 1.4×	182 0.7×	151	2.4k
Massimo Martino Italy	23	1.1k 0.8×	428 0.6×	750 1.0×	220 0.8×	143 0.5×	152	1.8k
Edward N. Libby United States	22	1.2k 0.9×	1.1k 1.5×	1.1k 1.5×	268 1.0×	52 0.2×	87	2.5k
Agnieszka Wierzbowska Poland	22	1.5k 1.1×	1.1k 1.5×	483 0.6×	461 1.7×	435 1.6×	108	2.3k
Heather Oakervee United Kingdom	19	1.2k 0.9×	888 1.2×	639 0.9×	184 0.7×	121 0.4×	42	1.6k
Leonard T. Heffner United States	21	1.1k 0.8×	687 0.9×	717 1.0×	299 1.1×	140 0.5×	68	1.7k
Robert M. Rifkin United States	26	1.6k 1.2×	1.4k 1.9×	1.2k 1.5×	248 0.9×	115 0.4×	143	2.5k
Nigel Westwood United Kingdom	21	913 0.7×	767 1.0×	480 0.6×	862 3.2×	67 0.2×	68	2.2k
Vamsi Kota United States	19	887 0.6×	397 0.5×	408 0.5×	397 1.5×	179 0.7×	156	1.4k

Countries citing papers authored by Qaiser Bashir

Since Specialization

Citations

This map shows the geographic impact of Qaiser Bashir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qaiser Bashir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qaiser Bashir more than expected).

Fields of papers citing papers by Qaiser Bashir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qaiser Bashir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qaiser Bashir. The network helps show where Qaiser Bashir may publish in the future.

Co-authorship network of co-authors of Qaiser Bashir

This figure shows the co-authorship network connecting the top 25 collaborators of Qaiser Bashir. A scholar is included among the top collaborators of Qaiser Bashir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qaiser Bashir. Qaiser Bashir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oran, Betül, David Marin, Qaiser Bashir, et al.. (2024). Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML. Blood. 144(Supplement 1). 1497–1497. 1 indexed citations

Ciurea, Stefan O., Uday Popat, Jeremy Ramdial, et al.. (2024). Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Advances. 8(12). 3237–3245. 2 indexed citations

Joseph, Jacinth, Samer A. Srour, Denái R. Milton, et al.. (2023). Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and Cellular Therapy. 29(12). 770.e1–770.e6. 3 indexed citations

Pasvolsky, Oren, Roland L. Bassett, Hina Khan, et al.. (2023). Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 130(9). 1663–1672. 1 indexed citations

Bashir, Qaiser, Marc Braunstein, Murali Janakiram, et al.. (2023). Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion. Transplantation and Cellular Therapy. 29(11). 666–673. 7 indexed citations

Al‐Juhaishi, Taha, Yingjun Wang, Denái R. Milton, et al.. (2023). Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplantation. 58(9). 1000–1007. 3 indexed citations

Pasvolsky, Oren, Denái R. Milton, Mark R. Tanner, et al.. (2023). Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplantation and Cellular Therapy. 29(12). 757–762. 8 indexed citations

Patel, Krina K., Jatin J. Shah, Hans C. Lee, et al.. (2022). Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clinical Cancer Research. 28(7). 1277–1284. 7 indexed citations

Qazilbash, Muzaffar H., Penny Fang, Susan Wu, et al.. (2022). Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 29(1). 37.e1–37.e7. 2 indexed citations

10.

Bashir, Qaiser, Taiga Nishihori, Marcelo C. Pasquini, et al.. (2022). A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial. Transplantation and Cellular Therapy. 29(6). 358.e1–358.e7. 5 indexed citations

11.

Pasvolsky, Oren, Denái R. Milton, Mark R. Tanner, et al.. (2022). Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplantation and Cellular Therapy. 28(11). 752.e1–752.e6. 4 indexed citations

12.

Ciurea, Stefan O., Piyanuch Kongtim, Doris Soebbing, et al.. (2021). Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 36(1). 155–164. 65 indexed citations

13.

Shah, Mithun Vinod, Rima M. Saliba, Ankur Varma, et al.. (2021). Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. British Journal of Haematology. 193(5). 1004–1008. 8 indexed citations

14.

Oran, Betül, Rima M. Saliba, Rohtesh S. Mehta, et al.. (2021). Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 127(10). 1598–1605. 3 indexed citations

15.

Lee, Hans C., Krina K. Patel, Sheeba K. Thomas, et al.. (2020). Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clinical Lymphoma Myeloma & Leukemia. 20(5). e221–e238. 9 indexed citations

16.

Lin, Paul, Rima M. Saliba, Uday Popat, et al.. (2019). Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biology of Blood and Marrow Transplantation. 25(5). 1039–1044. 10 indexed citations

17.

Ciurea, Stefan O., Piyanuch Kongtim, Ankur Varma, et al.. (2019). Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood. 135(6). 449–452. 28 indexed citations

18.

Ciurea, Stefan O., Doris Soebbing, Gabriela Rondón, et al.. (2017). Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation. Blood. 130. 3179–3179. 2 indexed citations

19.

Patel, Krina K., Jatin J. Shah, Lei Feng, et al.. (2017). Update on a Phase II Study of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood. 130. 437–437. 12 indexed citations

20.

Chaudhri, Naeem, Mahmoud Aljurf, Fahad Almohareb, et al.. (2017). Establishing an autologous versus allogeneic hematopoietic cell transplant program in nations with emerging economies. Hematology/Oncology and Stem Cell Therapy. 10(4). 173–177. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact